NCT00097721View on ClinicalTrials.gov

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

104

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions

Breast Neoplasms

Interventions

DRUG

E7389

The first cohort of subjects were to receive E7389 1.4 mg/m\^2 as an intravenous (IV) bolus on Days 1, 8, and 15 of a 28-day cycle. A second cohort of subjects was added and were to receive E7389 1.4 mg/m\^2 as an IV bolus on Days 1 and 8 of a 21-day cycle.

Trial Locations (16)

Unknown

Jonesboro

Deer Park

La Verne

Pasadena

Pomona

Brooksville

New Port Richey

Plantation

New Orleans

Southaven

Missoula

Syracuse

Middletown

Memphis

Amarillo

Richardson

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY

NCT00097721 - A Study of E7389 in Advanced/Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter